keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine neoplasm

keyword
https://www.readbyqxmd.com/read/29779696/preliminary-study-of-magnetically-controlled-capsule-gastroscopy-for-diagnosing-superficial-gastric-neoplasia
#1
Yang-Yang Qian, Shu-Guang Zhu, Xi Hou, Wei Zhou, Wei An, Xiao-Ju Su, Mark Edward McAlindon, Zhao-Shen Li, Zhuan Liao
BACKGROUND: Magnetically controlled capsule gastroscopy (MCCG) is a newly developed non-invasive method designed for gastric examination. Although favorable diagnostic accuracy has been reported, there is little if any data about its ability to diagnose gastric cancer. AIMS: To compare the detectability of superficial gastric neoplasia by MCCG and gastroscopy. METHODS: This study was a self-controlled comparison study. Ten subjects diagnosed with superficial gastric neoplasia and scheduled to undergo endoscopic submucosal dissection (ESD) at a tertiary hospital were prospectively invited for an MCCG examination...
April 24, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29776634/molecular-diagnostics-in-the-neoplasms-of-small-intestine-and-appendix-2018-update
#2
REVIEW
Yingtao Zhang, Muhammad Zulfiqar, Martin H Bluth, Amarpreet Bhalla, Rafic Beydoun
Neoplasms of the small intestine are rare in comparison with colorectal tumors. The most common tumor types arising in the small intestine are adenocarcinomas, well-differentiated neuroendocrine tumors, gastrointestinal stromal tumors, and lymphoma. Primary appendiceal neoplasms are rare and found in less than 2% of appendectomy specimens with an incidence of approximately 1.2 cases per 100,000 people per year in the United States. This article explores molecular diagnostics in the neoplasms of small intestine and appendix...
June 2018: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/29774940/-prognostic-analysis-and-clinicopathological-features-of-20-patients-with-appendiceal-neuroendocrine-neoplasms
#3
Weilin Mao, Yang Lyu, Ning Pu, Jian'ang Li, Baobao Xin, Wenqi Chen, Dayong Jin, Wenhui Lou, Xuefeng Xu
OBJECTIVE: To investigate clinicopathological features and prognostic factors of appendiceal neuroendocrine neoplasms(a-NEN). METHODS: Clinical data of 20 patients diagnosed with a-NEN at Zhongshan Hospital of Fudan University between January 2000 and December 2016 were retrospectively analyzed. Pathological diagnosis was based on the WHO classification criteria of digestive system tumors (2010 edition). Based on the mitotic count and Ki-67 index, a-NENs were divided into grade 1 neuroendocrine tumor (NET G1), grade 2(G2) NET G2) and grade 3 (neuroendocrine carcinoma, NEC)...
May 25, 2018: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29769293/emerging-multitarget-tyrosine-kinase-inhibitors-in-the-treatment-of-neuroendocrine-neoplasms
#4
Federica Grillo, Tullio Florio, Francesco Ferraù, Elda Kara, Giuseppe Fanciulli, Antongiulio Faggiano, Annamaria A L Colao
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multi-target tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by regulatory agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in depth review on the studies published on the following MTKIs in neuroendocrine tumours: axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed...
May 16, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29766455/consensus-document-on-the-progression-and-treatment-response-criteria-in-gastroenteropancreatic-neuroendocrine-tumors
#5
X Merino-Casabiel, J Aller, J Arbizu, R García-Figueiras, C González, E Grande, P Jiménez-Fonseca, M I Sevilla, J Capdevila
PURPOSE: Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should differ from other kind of tumors. METHODS: To answer relevant questions about which techniques are best in the assessment of progression or treatment response a RAND/UCLA-based consensus process was implemented...
May 15, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29763721/new-insights-into-hypoxia-related-mechanisms-involved-in-different-microvascular-patterns-of-bronchopulmonary-carcinoids-and-poorly-differentiated-neuroendocrine-carcinomas-role-of-ribonuclease-t2-rnaset2-and-hif-1-alpha
#6
Silvia Uccella, Stefano La Rosa, Debora Scaldaferri, Laura Monti, Roberta Maragliano, Elisa Sorrenti, Marzia Gariboldi, Roberto Taramelli, Fausto Sessa, Francesco Acquati
Ribonuclease T2 (RNASET2) is a pleiotropic and polyfunctional protein, which exerts several different activities in neoplastic cells since the early steps of tumor development. Besides having an antitumorigenic activity, RNASET2 inhibits both bFGF-induced and VEGF-induced angiogenesis and has a role as a stress-response, alarmin-like, protein. In this study, we investigated RNASET2 expression in well-differentiated and poorly differentiated neuroendocrine neoplasms of the lung (Lu-NENs), which are known to show clear-cut differences in morphology, biology and clinical behavior...
May 12, 2018: Human Pathology
https://www.readbyqxmd.com/read/29752349/paediatric-pancreatic-neuroendocrine-tumours-in-von-hippel-lindau-disease
#7
Samuel Matthew O'Toole, Anju Sahdev, Satya Bhattacharya, Roger Feakins, Evelien F Gevers, William Drake
Extract: Pancreatic neuroendocrine tumours (pNETs) are an established feature of von Hippel-Lindau disease (VHL), occurring in up to 17% of mutation carriers (Libutti et al. 2000; Blansfield et al. 2007; Erlic et al. 2010; Igarashi et al. 2014). The natural history of VHL-pNETs is poorly characterised with metastatic disease occurring in up to 25% of affected individuals (Erlic et al. 2010). Management of this unique pNET subgroup is complicated by the potential for multifocal and metachronous disease as well as extra-pancreatic VHL-related neoplasms (e...
May 11, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29746922/diabetes-and-pancreatic-neuroendocrine-tumours-which-interplays-if-any
#8
REVIEW
Marco Gallo, Rosaria Maddalena Ruggeri, Giovanna Muscogiuri, Genoveffa Pizza, Antongiulio Faggiano, Annamaria Colao
Pancreatic neuroendocrine tumours (PanNETs) represent an uncommon type of pancreatic neoplasm, whose incidence is increasing worldwide. As per exocrine pancreatic cancer, a relationship seems to exist between PanNETs and glycaemic alterations. Diabetes mellitus (DM) or impaired glucose tolerance often occurs in PanNET patients as a consequence of hormonal hypersecretion by the tumour, specifically affecting glucose metabolism, or due to tumour mass effects. On the other hand, pre-existing DM may represent a risk factor for developing PanNETs and is likely to worsen the prognosis of such patients...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29742518/immune-checkpoint-inhibitors-in-the-treatment-of-patients-with-neuroendocrine-neoplasia
#9
Matthias M Weber, Christian Fottner
BACKGROUND: Well-differentiated neuroendocrine neoplasms (NENs) are usually controlled by antiproliferative, local ablative and/or radionuclide therapies, whereas poorly differentiated NENs generally require cytotoxic chemotherapy. However, treatment options for patients with advanced/metastatic high-grade NENs remain limited. METHOD: Review of the literature and international congress abstracts on the efficacy and safety of immunotherapy by checkpoint inhibition in advanced/metastatic NENs...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29741203/peptide-receptor-radionuclide-therapy-for-advanced-gastroenteropancreatic-neuroendocrine-tumors-from-oncology-perspective
#10
Agnieszka Kolasińska-Ćwikła, Anna Łowczak, Katarzyna Maciejkiewicz Maciejkiewicz, Jarosław Bogdan Ćwikła
Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (somatostatin analogue - SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e.g. arising from the small bowel (often called carcinoid tumours), the pancreas, duodenum or stomach, but also from the large bowel or the lung and many other tissues (so called diffuse neuroendocrine system)...
2018: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/29740725/a-case-of-mixed-adenoneuroendocrine-carcinoma-manec-arising-in-barrett-s-esophagus-literature-and-review
#11
Tetsuro Kawazoe, Hiroshi Saeki, Keitaro Edahiro, Shotaro Korehisa, Daisuke Taniguchi, Kensuke Kudou, Ryota Nakanishi, Nobuhide Kubo, Koji Ando, Yuichiro Nakashima, Eiji Oki, Minako Fujiwara, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: Mixed adenoneuroendocrine carcinoma (MANEC) is defined as a neoplasm composed of both exocrine and endocrine carcinomas, each comprising at least 30% of the tumor. MANEC can occur in various organs of the gastrointestinal tract, including the esophagus, stomach, and colon. We herein provide the first case report of surgically resected MANEC arising in Barrett's esophagus (BE). CASE PRESENTATION: A 70-year-old man presenting with abdominal pain was referred to our hospital...
May 8, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29739948/a-meta-analysis-of-prognostic-factor-of-pancreatic-neuroendocrine-neoplasms
#12
Yong Gao, Hao Gao, Guangfu Wang, Lingdi Yin, Wenbin Xu, Yunpeng Peng, Junli Wu, Kuirong Jiang, Yi Miao
Pancreatic neuroendocrine neoplasms (pNENs) are a group of clinically rare and heterogeneous diseases of the pancreas. However, the prognostic factors for this disease in patients still remain controversial. The purpose of our study is to evaluate the predictive roles of those prognostic factors for pNENs. All related articles published until Sep 17, 2017 were identified via PubMed, EMBASE, Web of Science, Ovid and the Cochrane Library. Studies that examined the prognostic factors of pNENs were enrolled. 17 articles (2822 patients) were finally included in this study...
May 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29733523/pattern-and-risk-factors-for-distant-metastases-in-gastrointestinal-neuroendocrine-neoplasms-a-population-based-study
#13
Wen Cai, Yinuo Tan, Weiting Ge, Kefeng Ding, Hanguang Hu
An increased incidence of gastrointestinal neuroendocrine neoplasms (GI-NENs) has been reported worldwide, and metastasis is the leading cause of GI-NEN-related death. Studies of different metastatic patterns in patients with different primary sites are limited. A population-based retrospective cohort study was conducted with the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a GI-NEN diagnosis between 2010 and 2014 were included. All statistical analyses were performed using Intercooled Stata 12...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29732153/long-term-disease-free-survival-of-gastric-mixed-adenoneuroendocrine-carcinoma-treated-with-multimodality-therapy-a-case-report
#14
Guangjian Yang, Dan Li, Fangchao Zheng, Lin Yang
Gastric mixed adenoneuroendocrine carcinoma, a rare malignant type of stomach tumor, is composed of components of adenocarcinoma and neuroendocrine tumor. This type of neoplasm usually has a poor prognosis since both components are malignant. A 65-year-old male presented with norexia, epigastric distention, abdominal and lumbar pain. Contrast computed tomography scan of the abdomen verified multiple lesions merged into a large mass. Histolopathological examination of the specimen from digestive endoscopy was verified to be gastric mixed adenoneuroendocrine carcinoma...
May 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29727904/endoscopic-ultrasound-guided-radiofrequency-ablation-for-management-of-benign-solid-pancreatic-tumors
#15
Jun-Ho Choi, Dong-Wan Seo, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim
BACKGROUND:  Radiofrequency ablation (RFA) has been increasingly employed in experimental and clinical settings for the management of pancreatic lesions. This study aimed to assess the safety and efficacy of endoscopic ultrasound (EUS)-guided RFA for benign solid pancreatic tumors. METHODS:  In a single-center, prospective study, 10 patients with benign solid pancreatic tumors underwent EUS-RFA. After the RFA electrode had been inserted into the pancreatic mass, the radiofrequency generator was activated to deliver 50 W of ablation power...
May 4, 2018: Endoscopy
https://www.readbyqxmd.com/read/29726295/duodenal-neuroendocrine-neoplasms-a-still-poorly-recognized-clinical-entity
#16
Roberta Elisa Rossi, Emanuele Rausa, Federica Cavalcoli, Dario Conte, Sara Massironi
BACKGROUND: Duodenal neuroendocrine neoplasms (dNENs) are rare tumors, which usually show good prognosis. The optimal management of these tumors is still far from being clearly understood because of their rarity and the poor level of knowledge about their natural history. Herein, we have reviewed the literature on dNENs to collect and analyze the current data on epidemiology, diagnosis and management of these rare tumors. METHODS: Bibliographical searches were performed in PubMed, using the following keywords: duodenal neuroendocrine neoplasm; duodenum; gastrinoma; diagnosis; therapy; guidelines...
May 4, 2018: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29723285/vasostatin-1-a-novel-circulating-biomarker-for-ileal-and-pancreatic-neuroendocrine-neoplasms
#17
Andrea Corsello, Luigi Di Filippo, Sara Massironi, Federica Sileo, Anna Dolcetta Capuzzo, Marco Gemma, Claudia Carlucci, Claudio Cusini, Barbara Colombo, Alice Dallatomasina, Giulia Maria Franchi, Angelo Corti, Marco Federico Manzoni
BACKGROUND: Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). However, its accuracy as a tumor biomarker is relatively low because plasma CgA can increase also in patients with other diseases or in subjects treated with proton-pump inhibitors (PPIs), a class of widely-used drugs. METHODS: In the attempt to identify a more reliable biomarker for NENs, we investigated, by ELISA, the circulating levels of full-length CgA (CgA1-439) and of various CgA-derived fragments in 17 patients with ileal or pancreatic NENs, 10 healthy controls, and 21 healthy volunteers before and after treatment with PPIs...
2018: PloS One
https://www.readbyqxmd.com/read/29717222/paraneoplastic-limbic-encephalitis-associated-with-lung-cancer
#18
Kaini Shen, Yan Xu, Hongzhi Guan, Wei Zhong, Minjiang Chen, Jing Zhao, Longyun Li, Mengzhao Wang
Paraneoplastic limbic encephalitis (PLE) is a rare autoimmune neurological syndrome observed in lung cancer patients. We retrospectively investigated the clinical characteristics, treatment responses, and prognoses in 16 PLE patients who were subsequently diagnosed with lung cancer. Fifteen patients initially presented with disturbance of consciousness, 13 with disorientation, and 12 with seizures. Thirteen patients had autoantibodies, including eight with gamma aminobutyric acid B receptor (GABAB R) antibodies and eight with Hu antibodies...
May 1, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29714658/entering-the-third-decade-of-experience-with-octreotide-lar-in-neuroendocrine-tumors-a-review-of-current-knowledge
#19
Sara Pusceddu, Natalie Prinzi, Alessandra Raimondi, Francesca Corti, Roberto Buzzoni, Maria Di Bartolomeo, Ettore Seregni, Marco Maccauro, Jorgelina Coppa, Massimo Milione, Vincenzo Mazzaferro, Filippo de Braud
Gastroenteropancreatic neuroendocrine tumors (NETs) are a relatively rare group of heterogeneous neoplasms. The most significant advance in therapy of NETs has been the advent of the somatostatin analog octreotide, which represents a cornerstone in their management and dramatically changed the therapeutic landscape. Octreotide long-acting release (LAR) was developed to overcome some of the limitations of octreotide. Several clinical studies, including PROMID and RADIANT-2, have validated the clinical benefits of octreotide LAR in NETs, with tumor shrinkage in about 10% of patients and tumor stabilization in roughly half of cases...
April 1, 2018: Tumori
https://www.readbyqxmd.com/read/29696624/therapeutic-targeting-of-tumor-associated-macrophages-in-pancreatic-neuroendocrine-tumors
#20
Sebastian Krug, Rami Abbassi, Heidi Griesmann, Bence Sipos, Dominik Wiese, Peter Rexin, Annika Blank, Aurel Perren, Johannes Haybaeck, Stefan Hüttelmaier, Anja Rinke, Thomas M Gress, Patrick Michl
Pancreatic neuroendocrine tumors (PNETs) represent a heterogeneous group of neuroendocrine neoplasms with varying biological behaviour and response to treatment. Although targeted therapies have been shown to improve the survival for patients at advanced stage, resistance to current therapies frequently occurs during the course of therapy. Previous reports indicate that the infiltration of tumor-associated macrophages (TAMs) in PNETs might correlate with tumor progression and metastasis formation. We aimed to evaluate the prognostic and functional impact of TAMs in human PNETs in vitro and in vivo and to investigate the effect of therapeutic targeting TAMs in a genetic PNET mouse model...
April 26, 2018: International Journal of Cancer. Journal International du Cancer
keyword
keyword
85606
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"